Diabetes Self-Management Articles

These articles cover a wide range of subjects, from the most basic aspects of diabetes care to the nitty-gritty specifics.

Links not loading properly?

Some of our pages use Portable Document Format (PDF) files, which require Adobe Acrobat Reader. To download Acrobat Reader for free, visit www.adobe.com.

Sign up for our weekly e-mail newsletter and receive a FREE GIFT! Enter your e-mail below.

Learn more

Learn more about diabetes

Links to help you learn more about diabetes.

Ask a diabetes expert
Other diabetes resources
Browse article topics

 

New Tools 2009

by Alwa A. Cooper

ACTOplus met XR should not be taken by people who have heart failure, kidney disease, or metabolic acidosis (excessive acidity of the blood), or by people who drink excessive amounts of alcohol. People who take ACTOplus met XR should be screened for liver problems before and periodically while taking it, and people who already have liver disease should not take ACTOplus met XR.

Availability: ACTOplus met XR is available by prescription only and is expected to be on the market by the end of 2009.


Product: Saxagliptin (Onglyza)

Manufacturer: Bristol-Myers Squibb
(800) 321-1335
www.bms.com

AstraZeneca
(800) 236-9933
www.astrazeneca.com

What it does: Onglyza is the second drug — joining Merck’s sitaglipin (Januvia) — in a class called DPP-4 inhibitors to be approved by the FDA for the treatment of Type 2 diabetes. Like Januvia, it is currently approved only for use in adults. Onglyza can be taken alone or in combination with other diabetes drugs, including metformin, Actos, Avandia, and those in the sulfonylurea class, which includes glimepiride, glipizide, and glyburide. When taken with a sulfonylurea, a lower dose of Onglyza is recommended to prevent hypoglycemia (low blood glucose). Its use in combination with insulin has not been studied. Onglyza is taken once daily.

Availability: Onglyza is available in 2.5-mg or 5-mg tablets.

Drug labeling changes

Product: Glimepiride (Amaryl)

Manufacturer: Sanofi-aventis
(800) 981-2491
www.sanofi-aventis.us

Reason for label change: Several classes of drugs that can increase the blood-glucose–lowering abilities of Amaryl, a sulfonylurea, to dangerous levels have already been identified by the FDA. This year the agency approved a labeling change that added disopyramide (Norpace and Rythmodan), fluoxetine (Prozac), and the quinolone family of antibiotics to the drugs that could cause hypoglycemia when taken in combination with Amaryl.


Product: Glyburide (Diabeta, Glynase, Micronase)

Manufacturer: various

Reason for label change: The drug glyburide, a sulfonylurea, is what is called “protein bound.” If taken with other drugs that are also protein bound — such as the non-steroidal anti-inflammatory drugs (NSAIDs), which include Celebrex, Motrin, Aleve, and aspirin — the risk of developing hypoglycemia is increased. The labeling change states that people who use glyburide with other protein-bound drugs should be observed closely for low blood glucose.


Product: Insulin aspart (NovoLog)

Manufacturer: Novo Nordisk
(800) 727-6500
www.novonordisk.com

Page    1    2    3    4    5    6    7    8    9    10    Show All    

 

 

More articles on Tools & Technology

 

 


Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information provided on this Web site should not be construed as medical instruction. Consult appropriate health-care professionals before taking action based on this information.

 

 

Disability Resources
Diabetes can cause a number of complications, including some that can affect your ability to... Article

Staying Heart Healthy
Are you at risk for heart disease? Everyone has some risk of eventually developing heart disease,... Article

Getting Started Exercising
Regular exercise is good for everyone: It keeps the heart healthy and joints and muscles strong,... Article

What should I keep in mind if I'm switching from syringes to insulin pens? Get tip